Dilated cardiomyopathy other diagnostic studies

Revision as of 21:37, 12 December 2019 by Sabawoon Mirwais (talk | contribs)
Jump to navigation Jump to search

Dilated cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Classification

Causes

Differentiating Dilated cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Dilated cardiomyopathy other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Dilated cardiomyopathy other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dilated cardiomyopathy other diagnostic studies

CDC on Dilated cardiomyopathy other diagnostic studies

Dilated cardiomyopathy other diagnostic studies in the news

Blogs on Dilated cardiomyopathy other diagnostic studies

Directions to Hospitals Treating Dilated cardiomyopathy

Risk calculators and risk factors for Dilated cardiomyopathy other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Endomyocardial biopsy has low sensitivy and the findings are also notoriously non-specific. The findings on biopsy usually involve findings of inflammation and specific pathogens are unlikely to be identified. There may be an increased yield to using MRI to target endomyocardial biopsy. Viral titiers (serologies) are often unhelpful and not routinely ordered in clinical practice. About 40 genes are c.urrently included in genetic testing; however, mutations in >60 other genes have been linked to FCD, but are yet to be included.

Other Diagnostic Studies

Genetic Testing

  • FCD is primarily an autosomal dominant disease; however, cases with autosomal recessive or X-linked inheritance have been recognized.
  • Genetic studies have revealed an underlying genetic mutation in 30 to 40% of patients with FCD.[1]
  • About 40 genes are currently included in genetic testing; however, mutations in >60 other genes have been linked to FCD, but are yet to be included.
  • A full list of the genes that have been associated with DCM can be found in the Pathophysiology section.
  • A cohort study by Haas et al. showed that the genetic mutations in FCD overlap with other cardiomyopathies, highlighting the value of genetic testing in different types of cardiomyopathy.[2]
  • Current studies are focusing on the role of multiple mutations, enhancer region mutations, copy number variation, and intronic variants.[3]

Endometrial Biopsy

References

  1. McNally EM, Golbus JR, Puckelwartz MJ (2013). "Genetic mutations and mechanisms in dilated cardiomyopathy". J Clin Invest. 123 (1): 19–26. doi:10.1172/JCI62862. PMC 3533274. PMID 23281406.
  2. McNally EM, Golbus JR, Puckelwartz MJ (2013). "Genetic mutations and mechanisms in dilated cardiomyopathy". J Clin Invest. 123 (1): 19–26. doi:10.1172/JCI62862. PMC 3533274. PMID 23281406.
  3. Sweet M, Taylor MR, Mestroni L (2015). "Diagnosis, prevalence, and screening of familial dilated cardiomyopathy". Expert Opin Orphan Drugs. 3 (8): 869–876. doi:10.1517/21678707.2015.1057498. PMC 4988677. PMID 27547593.

Template:WS

References

Template:WH Template:WS